tetano
Editor, Senior Moderator
Clin Hematol Int
. 2021 Apr 16;3(3):77-82.
doi: 10.2991/chi.k.210403.001. eCollection 2021 Sep.
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
Francesco Lanza[SUP] 1 [/SUP], Vanessa Agostini[SUP] 2 [/SUP], Federica Monaco[SUP] 1 [/SUP], Francesco Passamonti[SUP] 3 [/SUP], Jerard Seghatchian[SUP] 4 [/SUP]
Affiliations
Abstract
The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of diseases, and was recently proposed by the World Health Organization for human Ebola virus infection. Only a few small studies have so far been published on patients with COVID-19 and concomitant hematological malignancies (HM). The Italian Hematology Alliance on HM and COVID-19 has found that HM patients with COVID-19 clinically perform more poorly than those with either HM or COVID-19 alone. A COVID-19 infection in patients with B-cell lymphoma is associated with impaired generation of neutralizing antibody titers and lowered clearance of SARS-CoV-2. Treatment with CP was seen to increase antibody titers in all patients and to improve clinical response in 80% of patients examined. However, a recent study has reported impaired production of SARS-CoV-2-neutralizing antibodies in an immunosuppressed individual treated with CP, possibly supporting the notion of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. This may limit the efficacy of CP treatment in at least some HM patients. More recently, it has been shown that CP may provide a neutralising effect against B.1.1.7 and other SARS-CoV-2 variants, thus expanding its application in clinical practice. More extensive studies are needed to further assess the use of CP in COVID-19-infected HM patients.
Keywords: COVID-19 antibodies; COVID-19 mutation; SARS-CoV-2; convalescent plasma preparations; hematological disorders; neutralising antibodies; plasmapheresis; prolonged viral shedding.
. 2021 Apr 16;3(3):77-82.
doi: 10.2991/chi.k.210403.001. eCollection 2021 Sep.
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
Francesco Lanza[SUP] 1 [/SUP], Vanessa Agostini[SUP] 2 [/SUP], Federica Monaco[SUP] 1 [/SUP], Francesco Passamonti[SUP] 3 [/SUP], Jerard Seghatchian[SUP] 4 [/SUP]
Affiliations
- PMID: 34820612
- PMCID: PMC8486975
- DOI: 10.2991/chi.k.210403.001
Abstract
The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of diseases, and was recently proposed by the World Health Organization for human Ebola virus infection. Only a few small studies have so far been published on patients with COVID-19 and concomitant hematological malignancies (HM). The Italian Hematology Alliance on HM and COVID-19 has found that HM patients with COVID-19 clinically perform more poorly than those with either HM or COVID-19 alone. A COVID-19 infection in patients with B-cell lymphoma is associated with impaired generation of neutralizing antibody titers and lowered clearance of SARS-CoV-2. Treatment with CP was seen to increase antibody titers in all patients and to improve clinical response in 80% of patients examined. However, a recent study has reported impaired production of SARS-CoV-2-neutralizing antibodies in an immunosuppressed individual treated with CP, possibly supporting the notion of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. This may limit the efficacy of CP treatment in at least some HM patients. More recently, it has been shown that CP may provide a neutralising effect against B.1.1.7 and other SARS-CoV-2 variants, thus expanding its application in clinical practice. More extensive studies are needed to further assess the use of CP in COVID-19-infected HM patients.
Keywords: COVID-19 antibodies; COVID-19 mutation; SARS-CoV-2; convalescent plasma preparations; hematological disorders; neutralising antibodies; plasmapheresis; prolonged viral shedding.